ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01273259
Recruitment Status : Unknown
Verified January 2011 by University Hospital, Bordeaux.
Recruitment status was:  Not yet recruiting
First Posted : January 10, 2011
Last Update Posted : January 10, 2011
Sponsor:
Information provided by:
University Hospital, Bordeaux

Brief Summary:
DHEA prevents and reverses chronic hypoxic pulmonary hypertension in a chronic hypoxic-pulmonary hypertension model in the rat. However, no study has been performed in human. The purpose of this study is to determine if DHEA is effective in the treatment of respiratory pulmonary hypertension in adults with Chronic Obstructive Pulmonary Disease (COPD) on exercise capacity and haemodynamic variables. Patients will receive after randomisation either 25 mg/day or 200mg/day oral DHEA over a one-year period. Evaluation concerns clinical parameters, echocardiography and right catheterization after and before treatment. Primary end-point is the six-minute walk test. This is a prospective double blind, randomised, placebo controlled study which will be realized in four university hospitals in France : Bordeaux, Strasbourg, Toulouse and Limoges.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Hypertension, Pulmonary Drug: DHEA Treatment Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults. Phase 2 Trial
Study Start Date : January 2011
Estimated Primary Completion Date : March 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Prasterone
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 200 mg /day arm Drug: DHEA Treatment
DHEA : 200 mg/day hard gelatine capsule
Experimental: 25 mg/day arm Drug: DHEA Treatment
DHEA : 25 mg/day hard gelatine capsule



Primary Outcome Measures :
  1. Efficacy of DHEA on exercise capacity (six-minute walk test) [ Time Frame: inclusion and one year of treatment ]

Secondary Outcome Measures :
  1. Pulmonary and systemic arterial pressures (mean, systolic and diastolic) [ Time Frame: Inclusion and after one year of treatment ]
  2. Pulmonary vascular resistances [ Time Frame: Inclusion and after one year of treatment ]
  3. Safety / Compliance [ Time Frame: along one year of treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years old and ≤ 75 years old
  • Chronic Obstructive Pulmonary Disease with FEVs/VC < 70% (*)
  • Respiratory pulmonary hypertension with mean pulmonary arterial pressure ≥ 20 mmHg (*) related to normal pulmonary capillar pressure assessed by catheterization of the right side of the heart (pulmonary capillary wedge pressure ≤12mmHg)
  • PO2 ≤ 70 mmHg assessed by arterial gasometry at ease
  • If oxygenotherapy then oxygenotherapy more than 6 months before pre-screening
  • Written informed consent

(*) Criteria assessed from last health check or the last exams for COPD diagnosis

Exclusion Criteria:

  • clinical instability and/or respiratory exacerbation dangerous for catheterization
  • Pregnancy (ßHCG > 20 UI /l) or breastfeeding on going
  • General corticotherapy > 0,5 mg/kg/day prednisolon equivalent
  • Hepatic insufficiency (TP < 50%) or renal insufficiency (creatininemia > 130 µmol/l) or diabetes mellitus type I or II (treated by oral antidiabetic or insulin)
  • Left-heart failure (coronary heart disease and/or left valvulopathy)
  • High level of prostatic specific antigen (PSA) (> 7ng/ml)
  • Cancer antecedent or treatment on going

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01273259


Contacts
Contact: Eric Dumas De La Roque, Dr eric.dumas-de-la-roque@chu-bordeaux.fr
Contact: Fabienne Nacka, phD fabienne.nacka@chu-bordeaux.fr

Locations
France
University Hospital, Bordeaux Recruiting
Bordeaux, France
Principal Investigator: Claire Dromer, Dr         
Sub-Investigator: Douard, Pr         
Sub-Investigator: Marc Billes, Dr         
Sub-Investigator: Rean, Dr         
Principal Investigator: Benissan, Pr         
Sub-Investigator: Bui, Dr         
CHU de Limoges
Limoges, France
CHU de Strasbourg
Strasbourg, France
CHU de Toulouse
Toulouse, France
Sponsors and Collaborators
University Hospital, Bordeaux

Responsible Party: Jean-Pierre LEROY / Clinical Research and Innovation Director, University Hospital, Bordeaux
ClinicalTrials.gov Identifier: NCT01273259     History of Changes
Other Study ID Numbers: CHUBX 2003/04
First Posted: January 10, 2011    Key Record Dates
Last Update Posted: January 10, 2011
Last Verified: January 2011

Keywords provided by University Hospital, Bordeaux:
Hypertension, pulmonary
DHEA
six-minute walk test
pulmonary arterial pressure

Additional relevant MeSH terms:
Hypertension, Pulmonary
Hypertension
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Vascular Diseases
Cardiovascular Diseases
Respiratory Tract Diseases
Dehydroepiandrosterone
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs